← 返回专利悬崖列表
CAS 107-21-1
1,2-Dihydroxyethaneethane-1,2-diol
登记编号：101438-16-a、(IV)409139-6-a、CRISA-006、Tamsulosin Hydrochloride-108、MACI-010、BOSE-009、Nabilone-001
应用背景（按来源药适应症）
乳腺癌Paclitaxel/Encequidar mesylate腺癌Paclitaxel/Encequidar mesylate血管肉瘤Paclitaxel/Encequidar mesylate实体瘤Paclitaxel/Encequidar mesylate转甲状腺素运载蛋白淀粉样变性氯苯唑酸心脏病氯苯唑酸特应性皮炎克立硼罗皮炎克立硼罗湿疹克立硼罗斑秃克立硼罗局部硬皮病克立硼罗斑块银屑病克立硼罗勃起功能障碍他达拉非/坦洛新前列腺增生他达拉非/坦洛新肺动脉高压马昔腾坦肺性高血压马昔腾坦慢性病马昔腾坦慢性血栓栓塞性肺高压马昔腾坦血栓栓塞马昔腾坦心绞痛马昔腾坦下尿路症状琥珀酸索利那新/盐酸坦洛新前列腺增生琥珀酸索利那新/盐酸坦洛新膀胱过度活动症琥珀酸索利那新/盐酸坦洛新药物相关的副作用和不良反应琥珀酸索利那新/盐酸坦洛新膀胱颈梗阻琥珀酸索利那新/盐酸坦洛新前列腺增生度他雄胺/盐酸坦洛新前列腺增生盐酸坦洛新泌尿系统感染盐酸坦洛新尿潴留盐酸坦洛新腹股沟疝盐酸坦洛新排尿功能障碍盐酸坦洛新下尿路症状盐酸坦洛新胰腺癌紫杉醇非小细胞肺癌紫杉醇霍奇金病紫杉醇精原细胞瘤紫杉醇卵巢癌紫杉醇乳腺癌紫杉醇溃疡波生坦肺动脉高压波生坦肺性高血压波生坦系统性硬皮病波生坦冠状血管痉挛波生坦大动脉炎波生坦瘙痒症大麻隆终末期肾脏病大麻隆恶心大麻隆呕吐大麻隆强迫性障碍大麻隆自杀意念大麻隆
来源药（使用该中间体的合成路线）
| 品种 | 梯队 | 到期年 |
|---|---|---|
| Paclitaxel/Encequidar mesylate | Tier C · 观察 / 贸易 | - |
| 氯苯唑酸Tafamidis | Tier C · 观察 / 贸易 | - |
| 克立硼罗Crisaborole | Tier C · 观察 / 贸易 | - |
| 他达拉非/坦洛新Tadalafil/Tamsulosin | Tier C · 观察 / 贸易 | - |
| 马昔腾坦Macitentan | Tier B · 提前布局 | - |
| 琥珀酸索利那新/盐酸坦洛新Solifenacin Succinate/Tamsulosin Hydrochloride | Tier C · 观察 / 贸易 | - |
| 度他雄胺/盐酸坦洛新Dutasteride/Tamsulosin Hydrochloride | Tier C · 观察 / 贸易 | - |
| 盐酸坦洛新Tamsulosin Hydrochloride | Tier C · 观察 / 贸易 | - |
| 紫杉醇Paclitaxel | Tier B · 提前布局 | - |
| 波生坦Bosentan Hydrate | Tier B · 提前布局 | - |
| 大麻隆Nabilone | Tier C · 观察 / 贸易 | - |
合成路线中的位置（上下游链）
按路线登记顺序排列，左→右为合成方向；高亮为当前 CAS，其余可点击跳转对应档案。
(4'aS,5'S)-4'a-methyl-3',4',4'a,5',6',7'-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-5'-ol→[(4'aS,5'S)-4'a-methyl-3',4',4'a,5',6',7'-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-5'-yloxy](tert-butyl)dimethylsilane→(4'aS,5'S,8'aS)-5'-[(tert-butyldimethylsilyl)oxy]-4'a-methyl-octahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-8'-one→(4'aS,5'S,8'aS)-5'-[(tert-butyldimethylsilyl)oxy]-4'a-methyl-3',4',4'a,5',6',8'a-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-8'-yl trifluoromethanesulfonate→(1S,2S,5R,7S,8S)-7-[(tert-butyldimethylsilyl)oxy]-2-hydroxy-8-methyl-4-oxatricyclo[6.4.0.0(2,5)]dodecan-11-one→methyl (4'aS,5'S,8'aS)-5'-[(tert-butyldimethylsilyl)oxy]-4'a-methyl-3',4',4'a,5',6',8'a-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-8'-carboxylate→(4'aS,5'S,8'aR)-5'-[(tert-butyldimethylsilyl)oxy]-4'a-methyl-3',4',4'a,5',6',8'a-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-8'-ylmethanol→(4'aS,5'S,7'R,8'S,8'aS)-5'-[(tert-butyldimethylsilyl)oxy]-8'-(hydroxymethyl)-4'a-methyl-octahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-7',8'-diol→(1'S,2'S,5'R,7'S,8'S)-7'-[(tert-butyldimethylsilyl)oxy]-8'-methyl-4'-oxaspiro[1,3-dioxolane-2,11'-tricyclo[6.4.0.0(2,5)]dodecane]-2'-ol→(1S,2S,5R,7S,8S)-7-[(tert-butyldimethylsilyl)oxy]-2-hydroxy-8-methyl-4-oxatricyclo[6.4.0.0(2,5)]dodec-9-en-11-one→(1S,2S,5R,7S,8S)-2,7-bis[(tert-butyldimethylsilyl)oxy]-8-methyl-4-oxatricyclo[6.4.0.0(2,5)]dodec-9-en-11-one→(1S,2S,3S,4S,6R)-1,4-bis[(tert-butyldimethylsilyl)oxy]-3-methyl-7-oxabicyclo[4.2.0]octane-2,3-dicarbaldehyde→(1S,2S,3S,4S,6R)-1,4-bis[(tert-butyldimethylsilyl)oxy]-2-(1,3-dioxolan-2-yl)-3-methyl-7-oxabicyclo[4.2.0]octane-3-carbaldehyde→[2-(2,4-dimethylpenta-1,3-dien-3-yl)-1,3-dithian-2-yl]lithium→(1'S,3'S,4'S,7'R,9'S,10'S)-4',9'-bis[(tert-butyldimethylsilyl)oxy]-1'-(methoxymethoxy)-10',14',17',17'-tetramethyl-6'-oxaspiro[1,3-dithiane-2,12'-tetracyclo[11.3.1.0(3,10).0(4,7)]heptadecan]-13'-ene-2',11'-dione→tert-butyl({[(1S,2S,3S,4S,6R)-4-[(tert-butyldimethylsilyl)oxy]-3-{[2-(2,4-dimethylpenta-1,3-dien-3-yl)-1,3-dithian-2-yl]carbonyl}-2-(1,3-dioxolan-2-yl)-3-methyl-7-oxabicyclo[4.2.0]octan-1-yl]oxy})dimethylsilane→(1S,2S,3S,4S,6R)-1,4-bis[(tert-butyldimethylsilyl)oxy]-3-{[2-(2,4-dimethylpenta-1,3-dien-3-yl)-1,3-dithian-2-yl]carbonyl}-3-methyl-7-oxabicyclo[4.2.0]octane-2-carbaldehyde→1-lithio-1-(methoxymethoxy)ethene→1-[(1S,2S,3S,4S,6R)-1,4-bis[(tert-butyldimethylsilyl)oxy]-3-{[2-(2,4-dimethylpenta-1,3-dien-3-yl)-1,3-dithian-2-yl]carbonyl}-3-methyl-7-oxabicyclo[4.2.0]octan-2-yl]-2-(methoxymethoxy)prop-2-en-1-one→1,2-Dihydroxyethane
1,3-Dichloro-5-(trimethoxymethyl)benzene→(±)-1,2,4-Butanetriol→1-(3,5-Dichlorophenyl)-2,7,8-trioxabicyclo[3.2.1]octane→1,2-Dihydroxyethane→2-(3,5-Dichlorophenyl)-2-methoxy-1,3-dioxolane→cis-Cyclohexane-1,3,5-triol→3-(3,5-Dichlorophenyl)-2,4,10-trioxaadamantane→(4-Carboxy-2-hydroxyphenyl)amine→2-(3,5-Dichlorophenyl)benzo[d]oxazole-6-carboxylic acid
1,3-Dioxolan-2-one→1-Hydroxy-2-ethoxybenzene→2-(2-Ethoxyphenoxy)ethanol→2-(2-Ethoxyphenoxy)ethyl mesylate→1,2-Dihydroxyethane→1,2-Dimethylsulfonyloxyethane→5-(2-Aminopropyl)-N-tert-butyl-2-methoxybenzene-1-sulfonamide→N-tert-Butyl-2-methoxy-5-(2-oxopropyl)benzene-1-sulfonamide→(±)-N-tert-Butyl-5-(2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl)-2-methoxybenzene-1-sulfonamide→(±)-5-(2-[[2-(2-Ethoxyphenoxy)ethyl]amino]propyl)-2-methoxybenzene-1-sulfonamide
2-(4-bromophenyl)acetic acid→methyl 2-(4-bromophenyl)acetate→dimethyl carbonate→dimethyl 2-(4-bromophenyl)malonate→formimidamide hydrochloride→5-(4-bromophenyl)pyrimidine-4,6-diol→5-(4-bromophenyl)-4,6-dichloropyrimidine→potassium (N-propylsulfamoyl)amide→MACI-009→ethane-1,2-diol→MACI-011→5-bromo-2-chloropyrimidine→sulfurisocyanatidic chloride→2-methylpropan-2-ol→tert-butyl chlorosulfonylcarbamate→propan-1-amine→tert-butyl N-propylsulfamoylcarbamate→MACI-018
本站可供应的对应中间体
同 CAS 多家在售供应横向对比；价格区间为供应方挂牌口径，实价以询价确认为准。
| 供应商 | 产品 | 价格区间 | 最小起订 | 货期 | 资质 | 操作 |
|---|---|---|---|---|---|---|
| Unibest Taizhou GMP-like Site | 2-BROMO-5-HYDROXYBENZALDEHYDE Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Qualified Partner — East China API Works | 4-(4-Bromo-3-formyl-phenoxy)-benzonitrile Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Nantong cGMP Site | 4-[4-bromo-3-(hydroxymethyl)phenoxy]benzonitrile Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Taizhou GMP-like Site | [2-bromo-5-(4-cyanophenoxy)phenyl]methyl acetate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
本页为中间体 CAS 注册档案：同 CAS 的多条路线登记已合并；后续供应商报价与买方需求以该 CAS 为主键撮合。